. 2022 Mar 14:1–11. doi: 10.1080/14760584.2022.2042257
© 2022 Informa UK Limited, trading as Taylor & Francis Group
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
Figure 2.
Key factors in expediting COVID-19 vaccine development and approval.